In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Altimmune (ALT – Research Report), with a price target of $12.00.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Patrick Trucchio has given his Buy rating due to a combination of factors surrounding Altimmune’s promising drug candidate, pemvidutide. The optimism stems from the upcoming Phase 2b IMPACT trial results expected in the second quarter of 2025, which are anticipated to confirm pemvidutide’s efficacy in treating metabolic dysfunction-associated steatohepatitis (MASH). The trial’s focus on resolving MASH and improving fibrosis could position pemvidutide as a leading treatment option, potentially creating significant value for shareholders.
Additionally, past clinical trials have shown pemvidutide’s capability in substantially reducing liver fat and weight loss, with noteworthy improvements in inflammation and fibrosis biomarkers. These results have bolstered confidence, especially following the FDA’s Fast Track designation for MASH. Pemvidutide’s unique benefits, including lean mass preservation and lipid-lowering effects, further differentiate it from current treatments, suggesting a promising path forward if approved for broader clinical use.
In another report released on January 27, B.Riley Financial also reiterated a Buy rating on the stock with a $20.00 price target.